journal article·2024-09-10Open access

Therapeutic effect of targeted antioxidant natural products

Sohini Mukherjee, Hitesh Chopra, Rajat Goyal, Sihao Jin, Zhenzhen Dong, Tanmoy Das, Tanima Bhattacharya

Discover Nano· Volume 19· Issue 1

Abstract

The exploration of targeted therapy has proven to be a highly promising avenue in the realm of drug development research. The human body generates a substantial amount of free radicals during metabolic processes, and if not promptly eliminated, these free radicals can lead to oxidative stress, disrupting homeostasis and potentially contributing to chronic diseases and cancers. Before the development of contemporary medicine with synthetic pharmaceuticals and antioxidants, there was a long-standing practice of employing raw, natural ingredients to cure a variety of illnesses. This practice persisted even after the active antioxidant molecules were known. The ability of natural antioxidants to neutralise excess free radicals in the human body and so prevent and cure a wide range of illnesses. The term "natural antioxidant" refers to compounds derived from plants or other living organisms that have the ability to control the production of free radicals, scavenge them, stop free radical-mediated chain reactions, and prevent lipid peroxidation. These compounds have a strong potential to inhibit oxidative stress. Phytochemicals (antioxidants) derived from plants, such as polyphenols, carotenoids, vitamins, and others, are central to the discussion of natural antioxidants. Not only may these chemicals increase endogenous antioxidant defenses, affect communication cascades, and control gene expression, but they have also shown strong free radical scavenging properties. This study comprehensively summarizes the primary classes of natural antioxidants found in different plant and animal source that contribute to the prevention and treatment of diseases. Additionally, it outlines the research progress and outlines future development prospects. These discoveries not only establish a theoretical groundwork for pharmacological development but also present inventive ideas for addressing challenges in medical treatment.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Curcumin's Biomedical Applications · Phytochemicals and Antioxidant Activities · Free Radicals and Antioxidants

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (100+)

Show source-provided references
1. Lobo V, Patil A, Phatak A, Chandra N. Free radicals, antioxidants and functional foods: Impact on human health. Pharmacogn Rev. 2010;4:118.10.4103/0973-7847.70902 ↗
2. Forman HJ, Zhang H. Targeting oxidative stress in disease: promise and limitations of antioxidant therapy. Nat Rev Drug Discov. 2021;20:689–709.10.1038/s41573-021-00233-1 ↗
3. Yuan H, Ma Q, Ye L, Piao G. The traditional medicine and modern medicine from natural products. Molecules. 2016. https://doi.org/10.3390/molecules21050559.10.3390/molecules21050559 ↗
4. Integrating Traditional Medicine in Health Care Available online: https://www.who.int/southeastasia/news/feature-stories/detail/integrating-traditional-medicine (accessed on 8 March 2024).
5. Goyal R, Mittal G, Khurana S, Malik N, Kumar V, Soni A, Chopra H, Kamal MA. Insights on quercetin therapeutic potential for neurodegenerative diseases and its nano-technological perspectives. Curr Pharm Biotechnol. 2023. https://doi.org/10.2174/1389201025666230830125410.10.2174/1389201025666230830125410 ↗
6. Chopra H, Sharma S, Yousaf S, Naseer R, Ahmed S, Baig AA. Applications of nanotechnology-based approaches for targeted delivery of nutraceuticals. Handb Nanotechnol Nutraceuticals. 2022. https://doi.org/10.1201/9781003244721-12.10.1201/9781003244721-12/APPLICATIONS-NANOTECHNOLOGY-BASED-APPROACHES-TARGETED-DELIVERY-NUTRACEUTICALS-HITESH-CHOPRA-SHIVANI-SHARMA-SABA-YOUSAF-RAHAT-NASEER-SHAKEEL-AHMED-ATIF-AMIN-BAIG ↗
7. Walia V, Kaushik D, Mittal V, Kumar K, Verma R, Parashar J, Akter R, Rahman MHMH, Bhatia S, Al-Harrasi A, et al. Delineation of neuroprotective effects and possible benefits of antioxidantstherapy for the treatment of Alzheimer’s diseases by targeting mitochondrial-derived reactive oxygen species: bench to bedside. Mol Neurobiol. 2022;59:657–80. https://doi.org/10.1007/s12035-021-02617-1.10.1007/s12035-021-02617-1 ↗
8. Zehiroglu C, Ozturk Sarikaya SB. The importance of antioxidants and place in today’s scientific and technological studies. J Food Sci Technol. 2019;56:4757–74.10.1007/s13197-019-03952-x ↗
9. Kotha RR, Tareq FS, Yildiz E, Luthria DL. Oxidative stress and antioxidants—a critical review on in vitro antioxidant assays. Antioxidants. 2022;11:2388.10.3390/antiox11122388 ↗
10. Birben E, Sahiner UM, Sackesen C, Erzurum S, Kalayci O. Oxidative stress and antioxidant defense. World Allergy Organ J. 2012;5:9–19.10.1097/WOX.0b013e3182439613 ↗
11. Poljsak B. Strategies for reducing or preventing the generation of oxidative stress. Oxid Med Cell Longev. 2011;2011(1): 194586.
12. Jena AB, Samal RR, Bhol NK, Duttaroy AK. Cellular red-ox system in health and disease: the latest update. Biomed Pharmacother. 2023;162:114606.10.1016/j.biopha.2023.114606 ↗
13. Lee SE, Park YS. The emerging roles of antioxidant enzymes by dietary phytochemicals in vascular diseases. Life. 2021;11:199.10.3390/life11030199 ↗
14. Apak R, Özyürek M, Güçlü K, Çapanoʇlu E. Antioxidant activity/capacity measurement 1 classification, physicochemical principles, mechanisms, and electron transfer (ET)-based assays. J Agric Food Chem. 2016;64:997–1027.10.1021/acs.jafc.5b04739 ↗
15. Darenskaya M, Kolesnikov S, Semenova N, Kolesnikova L. Diabetic nephropathy: significance of determining oxidative stress and opportunities for antioxidant therapies. Int J Mol Sci. 2023;24:12378.10.3390/ijms241512378 ↗
16. Ahmad KA, Yuan Yuan D, Nawaz W, Ze H, Zhuo CX, Talal B, Taleb A, Mais E, Qilong D. Antioxidant therapy for management of oxidative stress induced hypertension. Free Radic Res. 2017;51:428–38.10.1080/10715762.2017.1322205 ↗
17. Feng Y, Wang X. Antioxidant therapies for Alzheimer’s disease. Oxid Med Cell Longev. 2012;2012(1): 472932.
18. Moura FA, de Andrade KQ, dos Santos JCF, Araújo ORP, Goulart MOF. Antioxidant therapy for treatment of inflammatory bowel disease: Does it work? Redox Biol. 2015;6:617–39.10.1016/j.redox.2015.10.006 ↗
19. Luo M, Zhou L, Huang Z, Li B, Nice EC, Xu J, Huang C. Antioxidant therapy in cancer: rationale and progress. Antioxidants. 2022;11:1128.10.3390/antiox11061128 ↗
20. Teleanu RI, Chircov C, Grumezescu AM, Volceanov A, Teleanu DM. Antioxidant therapies for neuroprotection-a review. J Clin Med. 2019;8:1659.10.3390/jcm8101659 ↗
21. Collins AE, Saleh TM, Kalisch BE. Naturally occurring antioxidant therapy in Alzheimer’s disease. Antioxidants. 2022;11:213.10.3390/antiox11020213 ↗
22. Wang S, Teng H, Zhang L, Wu L. Association between dietary antioxidant intakes and chronic respiratory diseases in adults. World Allergy Organ J. 2024;17: 100851. https://doi.org/10.1016/j.waojou.2023.100851.10.1016/j.waojou.2023.100851 ↗
23. Vidavalur R, Otani H, Singal PK, Maulik N. Significance of wine and resveratrol in cardiovascular disease: French paradox revisited. Exp Clin Cardiol. 2006;11:217–25.
24. Li H, Xia N, Hasselwander S, Daiber A. Resveratrol and vascular function. Int J Mol Sci. 2019. https://doi.org/10.3390/ijms20092155.10.3390/ijms20092155 ↗
25. Chaplin A, Carpéné C, Mercader J. Resveratrol, metabolic syndrome, and gut microbiota. Nutrients. 2018. https://doi.org/10.3390/nu10111651.10.3390/nu10111651 ↗
26. Jang JY, Im E, Kim ND. Mechanism of resveratrol-induced programmed cell death and new drug discovery against cancer: a review. Int J Mol Sci. 2022. https://doi.org/10.3390/ijms232213689.10.3390/ijms232213689 ↗
27. Almatroodi SA, A Alsahli M, SM Aljohani A, Alhumaydhi FA, Babiker AY, Khan AA, Rahmani AH. Potential therapeutic targets of resveratrol, a plant polyphenol, and its role in the therapy of various types of cancer. Molecules. 2022;27(9):2665.10.3390/molecules27092665 ↗
28. Izzo C, Annunziata M, Melara G, Sciorio R, Dallio M, Masarone M, Federico A, Persico M. The role of resveratrol in liver disease: a comprehensive review from in vitro to clinical trials. Nutrients. 2021. https://doi.org/10.3390/nu13030933.10.3390/nu13030933 ↗
29. Nashine S, Nesburn AB, Kuppermann BD, Kenney MC. Role of resveratrol in transmitochondrial AMD RPE cells. Nutrients. 2020. https://doi.org/10.3390/nu12010159.10.3390/nu12010159 ↗
30. Dyck GJB, Raj P, Zieroth S, Dyck JRB, Ezekowitz JA. The effects of resveratrol in patients with cardiovascular disease and heart failure: a narrative review. Int J Mol Sci. 2019. https://doi.org/10.3390/ijms20040904.10.3390/ijms20040904 ↗
31. Prysyazhna O, Wolhuter K, Switzer C, Santos C, Yang X, Lynham S, Shah AM, Eaton P, Burgoyne JR. Blood pressure-lowering by the antioxidant resveratrol is counterintuitively mediated by oxidation of CGMP-dependent protein kinase. Circulation. 2019;140:126–37. https://doi.org/10.1161/CIRCULATIONAHA.118.037398.10.1161/CIRCULATIONAHA.118.037398 ↗
32. Movahed A, Ostovar A, Iranpour D, Thandapilly SJ, Raj P, Louis XL, Smoliga JM, Netticadan T. The efficacy of resveratrol in controlling hypertension: study protocol for a randomized, crossover, double-blinded. Placebo-Controlled Trial Trials. 2016;17:296. https://doi.org/10.1186/s13063-016-1426-x.10.1186/s13063-016-1426-x ↗
33. Theodotou M, Fokianos K, Mouzouridou A, Konstantinou C, Aristotelous A, Prodromou D, Chrysikou A. The effect of resveratrol on hypertension: a clinical trial. Exp Ther Med. 2017;13:295–301. https://doi.org/10.3892/etm.2016.3958.10.3892/etm.2016.3958 ↗
34. Fogacci F, Tocci G, Presta V, Fratter A, Borghi C, Cicero AFG. Effect of resveratrol on blood pressure: a systematic review and meta-analysis of randomized, controlled, clinical trials. Crit Rev Food Sci Nutr. 2019;59:1605–18. https://doi.org/10.1080/10408398.2017.1422480.10.1080/10408398.2017.1422480 ↗
35. Short Interval Resveratrol Trial in Cardiovascular Surgery - Full Text View - ClinicalTrials.Gov Available online: https://classic.clinicaltrials.gov/ct2/show/NCT03762096 (accessed on 9 March 2024).
36. Cardiovascular Health of Older Adults and Resveratrol (CORE) - Full Text View - ClinicalTrials.Gov Available online: https://classic.clinicaltrials.gov/ct2/show/NCT02909699 (accessed on 9 March 2024).
37. Gal R, Deres L, Toth K, Halmosi R, Habon T. The effect of resveratrol on the cardiovascular system from molecular mechanisms to clinical results. Int J Mol Sci. 2021;22:10152.10.3390/ijms221810152 ↗
38. Zhu N, Huang B, Jiang W. Targets of vitamin C with therapeutic potential for cardiovascular disease and underlying mechanisms: a study of network pharmacology. Front Pharmacol. 2021;11:591337.10.3389/fphar.2020.591337 ↗
39. Moser MA, Chun OK. Vitamin C and heart health: a review based on findings from epidemiologic studies. Int J Mol Sci. 2016. https://doi.org/10.3390/ijms17081328.10.3390/ijms17081328 ↗
40. Morelli MB, Gambardella J, Castellanos V, Trimarco V, Santulli G. Vitamin C and cardiovascular disease: an update. Antioxidants (Basel Switzerland). 2020. https://doi.org/10.3390/antiox9121227.10.3390/antiox9121227 ↗
41. Cardiovascular Health Through Vitamin C Intake - PCNA Available online: https://pcna.net/cardiovascular-health-through-vitamin-c-intake/ (accessed on 9 March 2024).
42. High Dose Vitamin C in Cardiac Surgery Patients - Full Text View - ClinicalTrials.Gov Available online: https://classic.clinicaltrials.gov/ct2/show/NCT02762331 (accessed on 9 March 2024).
43. Vitamin C in Cardiac Surgery Patients - Full Text View - ClinicalTrials.Gov Available online: https://classic.clinicaltrials.gov/ct2/show/NCT03123107 (accessed on 9 March 2024).
44. Rozemeijer S, de Grooth HJ, Elbers PWG, Girbes ARJ, den Uil CA, Dubois EA, Wils EJ, Rettig TCD, van Zanten ARH, Vink R, et al. Early high-dose vitamin c in post-cardiac arrest syndrome (VITaCCA): study protocol for a randomized, double-blind, multi-center. Placebo-Controlled Trial Trials. 2021. https://doi.org/10.1186/s13063-021-05483-3.10.1186/s13063-021-05483-3 ↗
45. Can Vitamins Help Prevent a Heart Attack? - Mayo Clinic Available online: https://www.mayoclinic.org/diseases-conditions/heart-disease/expert-answers/prevent-heart-attack/faq-20058253 (accessed on 9 March 2024).
46. Shah S, Shiekh Y, Lawrence JA, Ezekwueme F, Alam M, Kunwar S, Gordon DK. A systematic review of effects of vitamin E on the cardiovascular system. Cureus. 2021. https://doi.org/10.7759/cureus.15616.10.7759/cureus.15616 ↗
47. Rychter AM, Hryhorowicz S, Słomski R, Dobrowolska A, Krela-Kaźmierczak I. Antioxidant effects of vitamin E and risk of cardiovascular disease in women with obesity – a narrative review. Clin Nutr. 2022;41:1557–65.10.1016/j.clnu.2022.04.032 ↗
48. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. the heart outcomes prevention evaluation study investigators. N Engl J Med. 2000;342:154–60.10.1056/NEJM200001203420302 ↗
49. Lee IM, Cook NR, Gaziano JM, Gordon D, Ridker PM, Manson JAE, Hennekens CH, Buring JE. Vitamin E in the primary prevention of cardiovascular disease and cancer the women’s health study: a randomized controlled trial. JAMA. 2005. https://doi.org/10.1001/jama.294.1.56.10.1001/jama.294.1.56 ↗
50. Saremi A, Arora R. Vitamin E and cardiovascular disease. Am J Ther. 2010;17:e56-65. https://doi.org/10.1097/MJT.0b013e31819cdc9a.10.1097/MJT.0b013e31819cdc9a ↗
51. Wang M, Tang R, Zhou R, Qian Y, Di D. The protective effect of serum carotenoids on cardiovascular disease: a cross-sectional study from the general US adult population. Front Nutr. 2023. https://doi.org/10.3389/fnut.2023.1154239.10.3389/fnut.2023.1154239 ↗
52. Yang J, Zhang Y, Na X, Zhao A. β-carotene supplementation and risk of cardiovascular disease: a systematic review and meta-analysis of randomized controlled trials. Nutrients. 2022;14:1284.10.3390/nu14061284 ↗
53. Tavani A, La Vecchia C. β-Carotene and risk of coronary heart disease a review of observational and intervention studies. Biomed Pharmacother. 1999. https://doi.org/10.1016/S0753-3322(99)80120-6.10.1016/S0753-3322(99)80120-6 ↗
54. Cardona F, Andrés-Lacueva C, Tulipani S, Tinahones FJ, Queipo-Ortuño MI. Benefits of polyphenols on gut microbiota and implications in human health. J Nutr Biochem. 2013;24:1415–22.10.1016/j.jnutbio.2013.05.001 ↗
55. Cooper KA, Chopra M, Thurnham DI. Wine polyphenols and promotion of cardiac health. Nutr Res Rev. 2004. https://doi.org/10.1079/nrr200482.10.1079/nrr200482 ↗
56. Börzsei D, Sebestyén J, Szabó R, Lesi ZN, Pálszabó A, Pálszabó P, Szász A, Priksz D, Juhász B, Veszelka M, et al. Resveratrol as a promising polyphenol in age-associated cardiac alterations. Oxid Med Cell Longev. 2022. https://doi.org/10.1155/2022/7911222.10.1155/2022/7911222 ↗
57. Sari N, Katanasaka Y, Honda H, Miyazaki Y, Sunagawa Y, Funamoto M, Shimizu K, Shimizu S, Wada H, Hasegawa K, et al. Cacao bean polyphenols inhibit cardiac hypertrophy and systolic dysfunction in pressure overload-induced heart failure model mice. Planta Med. 2020. https://doi.org/10.1055/a-1191-7970.10.1055/a-1191-7970 ↗
58. Tangney CC, Rasmussen HE. Polyphenols, inflammation, and cardiovascular disease. Curr Atheroscler Rep. 2013. https://doi.org/10.1007/s11883-013-0324-x.10.1007/s11883-013-0324-x ↗
59. Khurana S, Venkataraman K, Hollingsworth A, Piche M, Tai TC. Polyphenols: benefits to the cardiovascular system in health and in aging. Nutrients. 2013;5:3779–827.10.3390/nu5103779 ↗
60. Hedayati N, Yaghoobi A, Salami M, Gholinezhad Y, Aghadavood F, Eshraghi R, Aarabi MH, Homayoonfal M, Asemi Z, Mirzaei H, et al. Impact of polyphenols on heart failure and cardiac hypertrophy: clinical effects and molecular mechanisms. Front Cardiovasc Med. 2023;10:1174816.10.3389/fcvm.2023.1174816 ↗
61. Behl T, Bungau S, Kumar K, Zengin G, Khan F, Kumar A, Kaur R, Venkatachalam T, Tit DM, Vesa CM, et al. Pleotropic effects of polyphenols in cardiovascular system. Biomed Pharmacother. 2020;130:110714.10.1016/j.biopha.2020.110714 ↗
62. Chopra H, Bibi S, Mohanta YK, Kumari S, Baig AA. Role of polyphenols in cardiovascular diseases in bioprospecting of tropical medicinal plants. Cham: Springer; 2023.
63. Goszcz K, Duthie GG, Stewart D, Leslie SJ, Megson IL. Bioactive polyphenols and cardiovascular disease: Chemical antagonists, pharmacological agents or xenobiotics that drive an adaptive response? Br J Pharmacol. 2017;174:1209–25.10.1111/bph.13708 ↗
64. Khan J, Deb PK, Priya S, Medina KD, Devi R, Walode SG, Rudrapal M. Dietary flavonoids: cardioprotective potential with antioxidant effects and their pharmacokinetic Toxicological and Therapeutic Concerns. Molecules. 2021;26:4021.10.3390/molecules26134021 ↗
65. Jubaidi FF, Zainalabidin S, Taib IS, Hamid ZA, Budin SB. The potential role of flavonoids in ameliorating diabetic cardiomyopathy via alleviation of cardiac oxidative stress, inflammation and apoptosis. Int J Mol Sci. 2021. https://doi.org/10.3390/ijms22105094.10.3390/ijms22105094 ↗
66. Suen, J.; Thomas, J.; Kranz, A.; Vun, S.; Miller, M. Effect of Flavonoids on Oxidative Stress and Inflammation in Adults at Risk of Cardiovascular Disease: A Systematic Review. Healthc. 2016, 4.10.3390/healthcare4030069 ↗
67. Ciumărnean L, Milaciu MV, Runcan O, Vesa SC, Răchisan AL, Negrean V, Perné MG, Donca VI, Alexescu TG, Para I, et al. The effects of flavonoids in cardiovascular diseases. Molecules. 2020;25:4320.10.3390/molecules25184320 ↗
68. Yan Q, Liu S, Sun Y, Chen C, Yang S, Lin M, Long J, Yao J, Lin Y, Yi F, et al. Targeting oxidative stress as a preventive and therapeutic approach for cardiovascular disease. J Transl Med. 2023;21:519.10.1186/s12967-023-04361-7 ↗
69. Mattioli R, Francioso A, Mosca L, Silva P. Anthocyanins: a comprehensive review of their chemical properties and health effects on cardiovascular and neurodegenerative diseases. Molecules. 2020;25:3809.10.3390/molecules25173809 ↗
70. Mozos I, Flangea C, Vlad DC, Gug C, Mozos C, Stoian D, Luca CT, Horbańczuk JO, Horbańczuk OK, Atanasov AG. Effects of anthocyanins on vascular health. Biomolecules. 2021;11:811.10.3390/biom11060811 ↗
71. Grassi D, Desideri G, Ferri C. Flavonoids: antioxidants against atherosclerosis. Nutrients. 2010;2:889–902.10.3390/nu2080889 ↗
72. Ponzo V, Goitre I, Fadda M, Gambino R, De Francesco A, Soldati L, Gentile L, Magistroni P, Cassader M, Bo S. Dietary flavonoid intake and cardiovascular risk: a population-based cohort study. J Transl Med. 2015;13:1–13. https://doi.org/10.1186/S12967-015-0573-2/TABLES/4.10.1186/S12967-015-0573-2/TABLES/4 ↗
73. McCullough ML, Peterson JJ, Patel R, Jacques PF, Shah R, Dwyer JT. Flavonoid intake and cardiovascular disease mortality in a prospective cohort of US adults. Am J Clin Nutr. 2012;95:454. https://doi.org/10.3945/AJCN.111.016634.10.3945/AJCN.111.016634 ↗
74. Peterson JJ, Dwyer JT, Jacques PF, Mccullough ML. Do flavonoids reduce cardiovascular disease incidence or mortality in US and European populations? Nutr Rev. 2012;70:491. https://doi.org/10.1111/J.1753-4887.2012.00508.X.10.1111/J.1753-4887.2012.00508.X ↗
75. Hooper L, Kroon PA, Rimm EB, Cohn JS, Harvey I, Le Cornu KA, Ryder JJ, Hall WL, Cassidy A. Flavonoids, flavonoid-rich foods, and cardiovascular risk: a meta-analysis of randomized controlled trials. Am J Clin Nutr. 2008;88:38–50. https://doi.org/10.1093/AJCN/88.1.38.10.1093/AJCN/88.1.38 ↗
76. Fusi F, Trezza A, Tramaglino M, Sgaragli G, Saponara S, Spiga O. The beneficial health effects of flavonoids on the cardiovascular system: focus on K+ channels. Pharmacol Res. 2020;152: 104625. https://doi.org/10.1016/J.PHRS.2019.104625.10.1016/J.PHRS.2019.104625 ↗
77. Gross M. Flavonoids and cardiovascular disease. Pharm Biol. 2004;42:21–35. https://doi.org/10.3109/13880200490893483.10.3109/13880200490893483 ↗
78. Kozłowska A, Szostak-Węgierek D. Targeting cardiovascular diseases by flavonols: an update. Nutrients. 2022. https://doi.org/10.3390/nu14071439.10.3390/nu14071439 ↗
79. Chen LIJUAN, Wu XIAOLI, Wang WEIWEI, Wang XIA, Ma J. Quercetin with lycopene modulates enzymic antioxidant genes pathway in isoproterenol cardiotoxicity in rats: cardioprotection by quercetin & lycopene. Libyan J Med. 2021. https://doi.org/10.1080/19932820.2021.1943924.10.1080/19932820.2021.1943924 ↗
80. Rutkowska M, Kolodziejczyk-Czepas J, Owczarek A, Zakrzewska A, Magiera A, Olszewska MA. Novel insight into biological activity and phytochemical composition of Sorbus Aucuparia L. fruits: fractionated extracts as inhibitors of protein glycation and oxidative/nitrative damage of human plasma components. Food Res Int. 2021. https://doi.org/10.1016/j.foodres.2021.110526.10.1016/j.foodres.2021.110526 ↗
81. Ibrahim RYM, Saber AA, Hammad HBI. The possible role of the seaweed ulva fasciata on ameliorating hyperthyroidism-associated heart inflammations in a rat model. Environ Sci Pollut Res. 2021. https://doi.org/10.1007/s11356-020-11036-z.10.1007/s11356-020-11036-z ↗
82. Hu J, Wang X, Cui X, Kuang W, Li D, Wang J. Quercetin prevents isoprenaline-induced myocardial fibrosis by promoting autophagy via regulating MiR-223-3p/FOXO3. Cell Cycle. 2021. https://doi.org/10.1080/15384101.2021.1932029.10.1080/15384101.2021.1932029 ↗
83. Khan SU, Lone AN, Khan MS, Virani SS, Blumenthal RS, Nasir K, Miller M, Michos ED, Ballantyne CM, Boden WE, et al. Effect of omega-3 fatty acids on cardiovascular outcomes: a systematic review and meta-analysis. eClinicalMedicine. 2021. https://doi.org/10.1016/j.eclinm.2021.100997.10.1016/j.eclinm.2021.100997 ↗
84. Jain AP, Aggarwal KK, Zhang P-Y. Omega-3 fatty acids and cardiovascular disease. Eur Rev Med Pharmacol Sci. 2015;19:441–5.
85. Yu F, Qi S, Ji Y, Wang X, Fang S, Cao R. Effects of Omega-3 fatty acid on major cardiovascular outcomes: a systematic review and meta-analysis. Med (United States). 2022;101:e29556.
86. Mohebi-Nejad A, Bikdeli B. Omega-3 supplements and cardiovascular diseases. Tanaffos. 2014;13:6.
87. Chaddha A, Eagle KA. Omega-3 fatty acids and heart health. Circulation. 2015;132:e350–2. https://doi.org/10.1161/CIRCULATIONAHA.114.015176.10.1161/CIRCULATIONAHA.114.015176 ↗
88. Thies F, Mills LM, Moir S, Masson LF. Cardiovascular benefits of lycopene: Fantasy or reality? Proc Nutr Soc. 2017;76:122–9.10.1017/S0029665116000744 ↗
89. Zeng J, Zhao J, Dong B, Cai X, Jiang J, Xue R, Yao F, Dong Y, Liu C. Lycopene protects against pressure overload-induced cardiac hypertrophy by attenuating oxidative stress. J Nutr Biochem. 2019. https://doi.org/10.1016/j.jnutbio.2019.01.002.10.1016/j.jnutbio.2019.01.002 ↗
90. Xu J, Hu H, Chen B, Yue R, Zhou Z, Liu Y, Zhang S, Xu L, Wang H, Yu Z. Lycopene protects against hypoxia/reoxygenation injury by alleviating ER stress induced apoptosis in neonatal mouse cardiomyocytes. PLoS ONE. 2015. https://doi.org/10.1371/journal.pone.0136443.10.1371/journal.pone.0136443 ↗
91. He Q, Zhou W, Xiong C, Tan G, Chen M. Lycopene attenuates inflammation and apoptosis in post-myocardial infarction remodeling by inhibiting the nuclear factor-ΚB Signaling pathway. Mol Med Rep. 2015. https://doi.org/10.3892/mmr.2014.2676.10.3892/mmr.2014.2676 ↗
92. Palozza P, Parrone N, Simone RE, Catalano A. Lycopene in atherosclerosis prevention: an integrated scheme of the potential mechanisms of action from cell culture studies. Arch Biochem Biophys. 2010;504:26–33.10.1016/j.abb.2010.06.031 ↗
93. McEneny J, Wade L, Young IS, Masson L, Duthie G, McGinty A, McMaster C, Thies F. Lycopene intervention reduces inflammation and improves HDL functionality in moderately overweight middle-aged individuals. J Nutr Biochem. 2013. https://doi.org/10.1016/j.jnutbio.2012.03.015.10.1016/j.jnutbio.2012.03.015 ↗
94. Li YF, Chang YY, Huang HC, Wu YC, Yang MD, Chao PM. Tomato juice supplementation in young women reduces inflammatory adipokine levels independently of body fat reduction. Nutrition. 2015. https://doi.org/10.1016/j.nut.2014.11.008.10.1016/j.nut.2014.11.008 ↗
95. Tierney AC, Rumble CE, Billings LM, George ES. Effect of dietary and supplemental lycopene on cardiovascular risk factors: a systematic review and meta-analysis. Adv Nutr. 2020;11:1453–88.10.1093/advances/nmaa069 ↗
96. Mozos I, Stoian D, Caraba A, Malainer C, Horbanczuk JO, Atanasov AG. Lycopene and vascular health. Front Pharmacol. 2018;9:521.10.3389/fphar.2018.00521 ↗
97. Bin-Jumah MN, Nadeem MS, Gilani SJ, Mubeen B, Ullah I, Alzarea SI, Ghoneim MM, Alshehri S, Al-Abbasi FA, Kazmi I. Lycopene: a natural arsenal in the war against oxidative stress and cardiovascular diseases. Antioxidants. 2022;11:232.10.3390/antiox11020232 ↗
98. Gajendragadkar PR, Hubsch A, Mäki-Petäjä KM, Serg M, Wilkinson IB, Cheriyan J. Effects of oral lycopene supplementation on vascular function in patients with cardiovascular disease and healthy volunteers: a randomised controlled trial. PLoS ONE. 2014. https://doi.org/10.1371/journal.pone.0099070.10.1371/journal.pone.0099070 ↗
99. Costa-Rodrigues J, Pinho O, Monteiro PRR. Can lycopene be considered an effective protection against cardiovascular disease? Food Chem. 2018;245:1148–53.10.1016/j.foodchem.2017.11.055 ↗
100. de la Monte SM. Insulin resistance and neurodegeneration: progress towards the development of new therapeutics for alzheimer’s disease. Drugs. 2017;77:47. https://doi.org/10.1007/S40265-016-0674-0.10.1007/S40265-016-0674-0 ↗